Arcturus Therapeutics Holdings Inc (ARCT)
27.45
+0.86
(+3.23%)
USD |
NASDAQ |
Jun 21, 16:00
27.44
0.00 (0.00%)
After-Hours: 20:00
Arcturus Therapeutics Holdings Research and Development Expense (TTM): 193.94M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 193.94M |
| December 31, 2023 | 192.13M |
| September 30, 2023 | 182.49M |
| June 30, 2023 | 169.10M |
| March 31, 2023 | 154.63M |
| December 31, 2022 | 147.75M |
| September 30, 2022 | 153.40M |
| June 30, 2022 | 161.11M |
| March 31, 2022 | 168.60M |
| December 31, 2021 | 173.76M |
| September 30, 2021 | 165.41M |
| June 30, 2021 | 137.71M |
| March 31, 2021 | 99.98M |
| December 31, 2020 | 57.85M |
| September 30, 2020 | 45.55M |
| June 30, 2020 | 34.91M |
| March 31, 2020 | 34.23M |
| December 31, 2019 | 33.64M |
| September 30, 2019 | 26.49M |
| June 30, 2019 | 23.41M |
| March 31, 2019 | 20.36M |
| December 31, 2018 | 16.98M |
| September 30, 2018 | 16.49M |
| Date | Value |
|---|---|
| June 30, 2018 | 16.08M |
| March 31, 2018 | 15.63M |
| December 31, 2017 | 13.74M |
| September 30, 2017 | 13.38M |
| June 30, 2017 | 16.22M |
| March 31, 2017 | 16.63M |
| December 31, 2016 | 17.93M |
| September 30, 2016 | 9.294M |
| June 30, 2016 | 5.747M |
| March 31, 2016 | 5.248M |
| December 31, 2015 | 5.476M |
| September 30, 2015 | 15.03M |
| June 30, 2015 | 20.94M |
| March 31, 2015 | 23.17M |
| December 31, 2014 | 25.10M |
| September 30, 2014 | 24.80M |
| June 30, 2014 | 18.11M |
| March 31, 2014 | 12.51M |
| December 31, 2013 | 7.066M |
| September 30, 2013 | 2.53M |
| June 30, 2013 | 0.582M |
| March 31, 2013 | 0.492M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
23.41M
Minimum
Jun 2019
193.94M
Maximum
Mar 2024
117.81M
Average
150.58M
Median
Research and Development Expense (TTM) Benchmarks
| Novavax Inc | 583.08M |
| Vaxart Inc | 67.53M |
| AIM ImmunoTech Inc | 10.84M |
| Protalix BioTherapeutics Inc | 14.13M |
| Armata Pharmaceuticals Inc | 32.18M |